VolitionRx Limited to Present at Conferences in March 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight
March 9, 2021 4:08 PM ESTCantor Fitzgerald analyst Kyle Mikson initiates coverage on VolitionRX (NYSE: VNRX) with a Overweight rating and a price target of $8.00.
The analyst comments "We are initiating coverage of VolitionRx (VNRX) with an Overweight rating and a 12-month price target of $8. The company is developing a suite of blood-based (liquid... More
